Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...
A cutting-edge gene therapy has been approved ... with severe sickle cell disease. Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing tool Crispr, which ...
A cutting-edge gene therapy has been approved for NHS use for some patients with severe sickle cell disease. Casgevy, also known as exa-cel, was the first treatment to be licensed using gene-editing ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...